Latest price of roselixizumab in 2025

Rozanolixizumab (Rozanolixizumab) is a monoclonal antibody targeting FcRn (neonatal Fc receptor). It was developed by the Belgian pharmaceutical company UCB and is suitable for the treatment of generalized myasthenia gravis (gMG; rare disease) . Its main mechanism is to rapidly reduce the concentration of pathogenic autoantibodies in the serum by inhibiting the recycling of IgG antibodies. It has shown clear efficacy in patients with acetylcholine receptor (AChR) antibody-positive and MuSK antibody-positive patients. This dual adaptation mechanism opens up new avenues for gMG treatment, which has significant clinical significance, especially for patients who are resistant or ineffective with traditional treatments.

At the application level, roselixizumab is a subcutaneous injection preparation, usually administered based on body weight, and the frequency of administration once a week is more conducive to patient compliance. At present, China has officially approved the drug for marketing, marking it as the first targeted biological agent in China to cover AChR and MuSK antibody-positive people. However, since the drug has just been officially launched in May 2025 and has not yet been included in the national medical insurance catalog, the pricing information has not been fully disclosed to the outside world.

From the overseas market, the original specification of roselixizumab is 280mg/2mL injection. Each box is priced at more than 6,000 US dollars, which is approximately more than 40,000 yuan. The cost varies according to the dosage and course of treatment. There is currently no generic version on the market, and global supply is still dominated by UCB. Due to the high price, patients generally hope to lower their medication threshold through assistance programs or medical insurance negotiations. At present, some commercial insurances in the European and American markets have begun to cover this drug, and the possibility of including it in medical insurance in China is also being gradually evaluated.

As the treatment of systemic myasthenia gravis becomes more precise, roselixizumab is expected to become an important treatment option in the field of neuroimmunology in the future with its target innovation and clinical breakthroughs. Its market attention and accessibility issues are worthy of continued tracking.

Reference materials:https://www.drugs.com/rystiggo.html